

55. (Amended) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
implanting a vascular prosthesis in the blood vessel; and  
releasing methylprednisolone and at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel, wherein the immunosuppressive substance is mizoribine.

B2  
56. (Amended) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
implanting a vascular prosthesis in the blood vessel; and  
releasing methylprednisolone and at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel, wherein methylprednisolone is released within a time period of 2 days to 3 months.

B3  
61. (New) A method as in claim 55, wherein methylprednisolone is released within a time period of 2 days to 3 months and mizoribine is released within a time period of 1 day to 45 days.

REMARKS

In the Office Action, the Examiner noted that: Claims 1-60 are pending in the application, of which Claims 1-36 are withdrawn from consideration; Claims 37-54 and 57-60 are rejected; and Claims 55-56 are objected to.

As of the present amendment, Claims 1-60 are pending in the application of which Claims 1-36 are withdrawn from consideration, and Claims 37-60 are under consideration.

Response to Office Action Paragraph 2 Objection to Specification

In the Office Action the disclosure was objected to because of informalities, namely, blank spaces on page 3 lines 18-21 which appear to be missing some information.